Gemelli BiotechFounded in Los Angeles and Raleigh, NC,, a company that specializes in improving health through precision diagnosis for gastrointestinal (GI), diseases, has raised $19M of Series A funding.
Blue Ox Healthcare Partners, Cedars-Sinai led the round, along with participation by Cedars-Sinai Carolina Angel Network, CerraCap ventures and several family offices.
Gemelli Biotech, founded by Matt Mitcho in 2018, is focused on improving the health of patients by offering precision diagnostics for GI disease. Gemelli Biotech uses biological discoveries from the microbiome to offer non-invasive precision diagnostics that enable clinicians to definitively diagnose scientifically validated biomarkers, as well as optimally treat GI disorders such SIBO, IMO and excess hydrogen sulfide.
Gemelli Biotech will use the funds to speed up the commercialization of its trio smart technology.® ibs smart® Precision diagnostic tests: This includes expanding sales and marketing throughout the US and scaling up laboratory and manufacturing capacities, as well its operational footprints of Raleigh and Los Angeles.
trio-smart, a clinical breath test, measures levels of hydrogen and methane to give clinicians and patients a better picture of their gut health. ibssmart, a patent-pending diagnostic blood test for postinfectious IBS (irritable bowel syndrome), is available. These products were jointly developed with Cedars-Sinai’s Medically Associated Science and Technology (MAST) program.